Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
80
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study

Huan Gao1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
,
Tao Tian1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2033-1291
ORCID Icon,
Suoni Li2 Department of Medical Oncology, Tumor Hospital of Shaanxi, Xi’an, People’s Republic of China
,
Yinbin Zhang3 Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1105-8131
ORCID Icon,
Xiao Fu1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
,
Xiaoqiang Zheng1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7150-2575
ORCID Icon,
Na Liu1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-2276-3108
ORCID Icon,
Aimin Jiang1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4092-342X
ORCID Icon,
Mengdi Ren1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
,
Xiaoni Zhang1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
,
Xuan Liang1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
,
Zhiping Ruan1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9467-7466
ORCID Icon,
Zhimin Geng4 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaCorrespondence[email protected]
&
Yu Yao1 Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 889-898 | Published online: 29 Jan 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
  • Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–1940. doi:10.1200/JCO.2011.40.538122529261
  • Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa090872120375404
  • André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–867. doi:10.1038/sj.bjc.660462819238628
  • Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006;95(7):848–852. doi:10.1038/sj.bjc.660333416969352
  • Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemoth Pharm. 2010;65(4):641–647. doi:10.1007/s00280-009-1069-7
  • Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30):4581–4586. doi:10.1200/JCO.2010.29.360520855823
  • Chen JS, Hsu C, Chiang NJ, et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol. 2015;26(5):943–949. doi:10.1093/annonc/mdv03525632066
  • Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188. doi:10.1016/S1470-2045(11)70301-122192731
  • Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574–581. doi:10.1002/cncr.2977826540314
  • Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–828. doi:10.1016/S1470-2045(14)70212-824852116
  • Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958. doi:10.1093/annonc/mdz40231566666
  • Sakai D, Kanai M, Kobayashi S, et al. 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol. 2018;29:viii205. doi:10.1093/annonc/mdy282
  • Siebenhüner AR, Seifert H, Bachmann H, et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer. 2018;18(1):72. doi:10.1186/s12885-017-3967-029325521
  • Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202. doi:10.1002/bjs.1077629405274
  • Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–667. doi:10.1200/JCO.18.0005030707660
  • Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673. doi:10.1016/S1470-2045(18)30915-X30922733
  • Kobayashi S, Nagano H, Tomokuni A, et al. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Ann Surg. 2019;270(2):230–237. doi:10.1097/SLA.000000000000286530339627
  • Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564. doi:10.1186/s12885-015-1498-026228433
  • Murakami Y, Uemura K, Sudo T, et al. Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg. 2011;15(6):1007–1016. doi:10.1007/s11605-011-1479-921547707
  • Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–1695. doi:10.1002/cncr.1083112365016
  • Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–1027. doi:10.1200/JCO.18.0217830856044
  • André T, Louvet C, Artru P, et al. A phase II study of gemcitabine and oxaliplatin (gemox) in advanced biliary adenocarcinoma (ABA). Preliminary results. Eur J Cancer. 2001;37:S19. doi:10.1016/S0959-8049(01)80552-9
  • André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339–1343. doi:10.1093/annonc/mdh35115319238
  • Cho M, Wang-Gillam A, Myerson R, et al. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB. 2015;17(7):587–593. doi:10.1111/hpb.1241325800066
  • Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepato-Bil-Pan Sci. 2015;22(11):789–794.
  • Toyoda M, Ajiki T, Fujiwara Y, et al. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004). Cancer Chemoth Pharma. 2014;73(6):1295–1301. doi:10.1007/s00280-014-2431-y
  • Eckel F, Brunner T, Jelic S. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v65–9. doi:10.1093/annonc/mdq16720555105
  • Li Y, Zhou Y, Hong Y, et al. The efficacy of different chemotherapy regimens for advanced biliary tract cancer: a systematic review and network meta-analysis. Front Oncol. 2019;9:441. doi:10.3389/fonc.2019.0044131192137
  • Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962. doi:10.1158/2159-8290.CD-17-024528818953
  • Woo SM, Lee WJ, Han SS, et al. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Chemotherapy. 2012;58(3):225–232. doi:10.1159/00033949922831988

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.